Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Columbia Laboratories names new board member
Mr Campbell is a manager and senior analyst for Dorset Management and a member of Knott Partners Management. Mr Campbell holds a BS degree from McGill University. Mr
Mr Campbell is a manager and senior analyst for Dorset Management and a member of Knott Partners Management. Mr Campbell holds a BS degree from McGill University. Mr
Cellumen’s cardiac hypertrophy panel is designed to simultaneously measure eight distinct toxicity indicators in drug compounds including mitochondrial function, oxidative stress, apoptosis, and cellular hypertrophy. By leveraging Cellumen’s
Study ADX10059-204 is a double-blind, placebo-controlled, multi-center European Phase IIb trial in about 90 gastroesophageal reflux disease (GERD) patients known to respond well to proton pump inhibitors (PPI).
This collaboration will allow the development of highly-targeted commercial information products and continuing medical education (CME) programs for physicians, based on aggregated, HIPAA-compliant patient information derived from individual
According to the company, the newly allowed claims include subject matter covering aspects of blood-based appendicitis testing. A notice of allowance generally completes the substantive examination of a
The Spirit small vessel trial is designed to study 250 patients at approximately 50 centers in the US. The primary endpoint is a composite measure of cardiac death,
The patent issued by the World Intellectual Property Organization covers a novel method for ApoE haplotyping using multiplex PCR. Seegene’s proprietary Dual Priming Oligonucleotide (DPO) technology is being
The synergy of RayBiotech’s innovative portfolio with SeraCare’s global reach and expertise in virology, serology, immunology and molecular biology supports the acceleration of biomedical research and product development,
Saint Maurice’s laboratories process 2,000 tests per day and include the following specialties: biochemistry, toxicology, hematology, microbiology and immunology. Twelve analyzers will be connected directly to EdgeLab via
The program consists of two Phase III clinical placebo-controlled trials, each enrolling approximately 320 patients. The two trials will enroll patients internationally at sites in Europe, the US,